December 2022

NEWS & COLUMNS

6-7 NEWS
Johnson & Johnson to acquire Abiomed in deal worth $16.6bn; WHO launches R&D efforts to identify pathogens that could cause pandemics

8-9 NEWS
Sanofi given EC approval for rare anaemia; GSK’s RSV vaccine accepted for accelerated assessment

10-11 CORONAVIRUS NEWS
EMA grants AZ’s Vaxzevria COVID-19 vaccine full marketing authorisation; EC approves Sanofi/GSK’s COVID-19 booster

12 DARWIN'S MEDICINE
How biotech's problems created opportunities for others

14 RETROSPECTIVE PROSPECTIVE
Looking back at the lessons learned in 2022 and what the new year may bring

15 PHARMA STRATEGIST’S BLOG
Understanding the five mistakes to avoid in order to ensure brand success

FEATURES

16-17 DRUG PRICING IN FRANCE 
With changes to the pricing and access processes such as the new Accord Cadre and the soon-to-be implemented ATU reform likely to impact pricing and access of orphan products in France, we look at how French payers have in the past valued rarity

18-19 ADDRESSING THE DIVERSITY ISSUE IN CLINICAL TRIALS
With certain ethnic groups consistently under-represented in clinical studies globally, patient-centric analytics can be used to design more diverse, inclusive and equitable trials

21-22 TRANSFORMING THE OUTLOOK FOR CARDIOVASCULAR DISEASE
As the leading cause of death globally, cardiovascular diseases need to be addressed with cost-effective and sustainable interventions

22-23 UNLOCKING THE POTENTIAL OF DATA SHARING
The impact of privacy issues on clinical trials and how these issues limit studies

16-17 RARE DRUG PRICING IN FRANCE